16th International AIDS Conference Toronto, Canada - August 13 - 18, 2006

HEPATITIS B AND C VIRUS COINFECTION AMONG PATIENTS WITH HIV IN TREAT ASIA HIV OBSERVATIONAL DATABASE

Int Conf AIDS. 2006 Aug 13-18;16 Abstract No. TuAb0302

J. Zhou¹, G. Dore¹, Y.-M.A. Chen², M. Law¹, on behalf of TREAT Asia HIV Observational Database
¹ National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia, ² National Yang Ming University, AIDS Prevention and Research Center, Taipei, Taiwan, Republic of China

BACKGROUND: This paper aims to assess hepatitis B (HBV) and hepatitis C (HCV) virus coinfection and the impact on response to antiretroviral treatment and overall survival among patients with HIV infection in the TREAT Asia HIV Observational Database (TAHOD).

METHODS: Change of CD4 count at 180 days and time to undetectable HIV viral load (<400 copies/mL) after initiation of first triple or more combination therapy were assessed. Factors associated with overall survival after entry to TAHOD were assessed using Cox proportional survival models. Treatment and diagnosis of CDC category B and C illnesses were included as time-dependent variables.

RESULTS: Up to December 2005, a total of 2979 patients have been recruited to TAHOD. HBsAg test was available for 1641 patients, with a HBV prevalence of 10.4%. HCV antibody test was available for 1469 patients, with a HCV prevalence of 10.4%. Mean CD4 change at 180 days after initiation of antiretroviral treatment was 131.9 cells/μL and patients with either HBV or HCV had a lower but non-significant CD4 change. Median days to reach undetectable viral load was 223 days and was not significantly associated with HBV or HCV. In univariate analysis, patients with HCV had increased mortality (unadjusted hazard ratio, HR 2.77, p=0.008). However, neither HBV (adjusted HR 0.82, 95% CI 0.25 – 2.69, p=0.745) nor HCV (adjusted HR 1.55, 0.66 – 3.68, p=0.317) was associated with increased mortality after adjustment for baseline CD4 count, HIV viral load, recept of antiretroviral treatment and HIV disease stage.

CONCLUSIONS: Hepatitis testing data are available on about half of the TAHOD patients, with both prevalence of HBV and HCV around 10%. No significant differences in terms of immunological and virological response to antiretroviral treatment combination were seen between patients with or without hepatitis. Overall survival was also similar in co-infected patients.

Download PDF of this abstract.

Download Power Point Presentation.

2006-08-13
TuAb0302

Copyright © 2006 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.